| Literature DB >> 36199327 |
Mina Adampourezare1,2, Mohammad Hasanzadeh2,3, Farzad Seidi4.
Abstract
DNA methylation as one of the most important epigenetic modifications has a critical role in regulating gene expression and drug resistance in treating diseases such as cancer. Therefore, the detection of DNA methylation in the early stages of cancer plays an essential role in disease diagnosis. The majority of routine methods to detect DNA methylation are very tedious and costly. Therefore, designing easy and sensitive methods to detect DNA methylation directly and without the need for molecular methods is a hot topic issue in bioscience. Here we provide an overview on the optical biosensors (including fluorescence, FRET, SERs, colorimetric) that have been applied to detect the DNA methylation. In addition, various types of labeled and label-free reactions along with the application of molecular methods and optical biosensors have been surveyed. Also, the effect of nanomaterials on the sensitivity of detection methods is discussed. Furthermore, a comprehensive overview of the advantages and disadvantages of each method are provided. Finally, the use of microfluidic devices in the evaluation of DNA methylation and DNA damage analysis based on smartphone detection has been discussed. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 36199327 PMCID: PMC9460980 DOI: 10.1039/d2ra03630d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Rearrangement of the DNA methylation patterns associated with tumorigenesis.[7]
Fig. 2(A) Schematic representation of the bio-assay for DNA methylation detection.[44] (B) Schematic diagram of nanobiosensor preparation steps for DNA methylation assay.[45] (C) Schematic description for label-free fluorescence assay of DNA methylation based on CNPs, SG and enzyme–linkage reactions.[48] (D) Schematic representation of direct detection of DNA methylation by CdTe QDs.[49] (E) A schematic illustration of the ultrasensitive detection of DNA methylation by gold-nanorods-based fluorescence resonance energy transfer (FRET) assay.[52] (F) Principle of Methylation Level Analysis of Cancer-Related Genes Using CCP-Based FRET Technique, together with the Chemical Structures of CCP and Fluorescein Used in the Detection.[53] (G) Schematic representation of a FRET based approach for the detection of methylated DNA.[54] (H) Detection procedures of cytosine methylation in DNA by the FRET probe based on UCNPs and AuNRs.[55]
Fig. 3(A) Schematic depiction of identification of DNA methylation detection via MS-qFRET technology.[56] (B) Schematic procedures for the detection of methylated DNA based on FRET using up-conversion nanoparticles (UCNPs) and intercalating dye.[57] (C) Schematic of QD-FLP, illustrating the improved design. After bissulfite conversion and PCR amplification with modified primers, the FLP distinguishes the target amplicon, thereby eliminating background noise from the non-specific PCR amplicons.[61] (D) Schematic illustration of the detection of DNA methylation based on QDs-FRET.[62] (E) Schematic illustration of the detection of DNA methylation based on QDs-FRET.[63]
Fig. 4(A) Methodological approach for the label-free and real-time detection of regional DNA methylation based on MIP and SPR.[70] (B) Scheme of the DNA methylation biosensor methodology.[72]
Fig. 5(A) Illustration of the proposed SERS strategy for detection of methylated DNA and its derivatives.[95] (B) Schematic illustration for simultaneous C and T single DNA base change detection by LCR (a), and DNA methylation analysis via simultaneous SERS nanotags detection on a gold surface array (b).[96]
Fig. 6(A) Strategy for total genomic methylation. Genomic DNA. (B) Strategy for gene-specific methylation. Genomic DNA.[99]
Fig. 7Scheme of genotyping by AS-HCR with colorimetric detection. (a) Mechanism of the AS-HCR method for identifying single-nucleotide variants from genomic DNA and (b) assembly for smartphone detection.[153]
Fig. 8Multimodal mobile microscopy device and schematics of RCA assays. (a and b) 3D schematic illustration of the inner structure and the optical design of the mobile-phone-based microscopy platform. (c and d) Photographs of the mobile-phone-based microscope from different viewing perspectives. Mobile phone screen of (d) shows a bright-field image of fixated A549 cells captured by the phone. (e) DNA sequencing sample preparation scheme: genomic DNA is restriction digested and the KRAS DNA fragment selectively circularized on KRAS selector probes attached to slides. The DNA fragments are ligated and amplified on the slide, and the RCA products sequenced by unchained SBL chemistry.[15,20] DNA sequencing reactions are then imaged through our mobile phone microscope. (f) Dual-colour mobile phone microscope image of a targeted SBL reaction of KRAS codon 12 in genomic DNA extracted from A427 cells which are heterogeneous for a KRAS codon 12 mutation. RCPs are either stained with Cy3 corresponding to base G (KRAS wild type), or Cy5 corresponding to base A (KRAS mutant). Scale bar, 50 mm. (g) Schematic diagram of in situ point mutation detection assay through padlock probes and RCA. KRAS mRNA is converted to cDNA, which is targeted by single-base-discriminating padlock probes. Mutant specific padlock probes are ligated and amplified through RCA. Wild-type-specific probes do not ligate on mutated KRAS cDNA and generate no RCP. (h) A full field of view image of the A549 cell line with in situ RCA detected codon 12 point mutations, imaged with our mobile phone fluorescence microscope. Scale bar, 200 mm (full field of view); Scale bar, 20 mm (inset).[154]
| Detection method | Biomarker | Clinical sample | Linear range | LOD | Nanomaterial | Sequences of detection probes | Ref. |
|---|---|---|---|---|---|---|---|
| Fluorescence | Adenomatous polyposis coli gene | Plasma | Un-methylated DNA: 1.6 × 10−15–6.6 × 10−13 M | 1.2 × 10−16 M | Fe3O4/Au core/shell, dipyridamole | SH-(CH2)6-5′-CCG TCG AAA ACC CGC CGA-3′ |
|
| Methylated DNA: 3.2 × 10−15–8.0 × 10−13 M | 3.1 × 10−16 M | ||||||
| Fluorescence and UV-Vis | Adenomatous polyposis coli gene | Plasma | 10−21–0.1 × 10−12 M | 1 zM | Carbon materials and an organic dye (thionine) | TCCGCTTCCCGACCCGCACTCCGC |
|
| Fluorescence and UV-Vis | Adenomatous polyposis coli gene | Plasma | 10−21–0.1 × 10−12 M | 1 zM | Carbon materials and an organic dye (toluidine blue) | TCCGCTTCCCGACCCGCACTCCGC |
|
| Fluorescence | 7.3 × 10−11 M | Graphene quantum dot and SYBER green as dye reporter |
| ||||
| Fluorescence | Adenomatous polyposis coli | — | 1.0 × 10−10 to 1.0 × 10−6 M | 6.2 × 10−11 M | CdTe quantum dots | 5′-TCCGCTTCCCGACCCGCACTCCGC-3′ |
|
| FRET | — | — | 40 nM | 0.25 U mL−1 | Gold nanorods | FAM-5′-CCTTTTGATCATTTT-FAM-3′ |
|
| FRET | RASSF1A, OPCML, and HOXA9 promoters | Ovarian cancer | 85.7% | Cationic conjugated polymer (CCP, poly{(1,4-phenylene)-2,7-[9,9-bis(6′- | RASSF1A |
| |
| F:5′-GGAGGCGCTGAAGTCGG-3′ | |||||||
| R:5′-GCCCAGCGGGTGCCA-3 | |||||||
| OPCML | |||||||
| 5′-GCCAGTGTCAGTTTTCAGTTTG-3′ | |||||||
| 5′-ATCCCTGACCGCCACTTT-3′ | |||||||
| HOXA9 | |||||||
| 5′-TGGACTCGTTCCTGCTGG-3′ | |||||||
| 5′-TGGTGGTGATGGTGGTGGTA-3′ | |||||||
| FRET | P53 tumor suppressor gene promoter | Human serum sample | 5 pM to 100 pM | 2.2 pM | Gold nanoparticle | 6′-FAM-5′-TCCGGTTCCCGACCCGGACTCCGCAAAAAA-3′-SH |
|
| FRET | — | 0–100 nM | — | Up-conversion nanoparticles (UCNPs) and gold nanorods (AuNRs) | Probe: biotin-5′-ATACCmGGTCTAAA-3′- |
| |
| MS-qFRET | p15INK4B | Cell lines, clinical samples from patients with acute myeloid leukemia. | — | — | Quantum dots | Primer sequences for p15INK4B: Methylated sense 5′-GGTTTTTTATTTTGTTAGAGCGAGGC-3′ |
|
| Methylated anti-sense 5′-TAACCGCAAAATACGAACGCG-3′ | |||||||
| Unmethylated sense 5′-GGTTGGTTTTTTATTTTGTTAGAGTGAGGT-3′ | |||||||
| Unmethylated anti-sense 5′-AACCACTCTA ACCACAAAATAC | |||||||
| AAACACA-3′ | |||||||
| MS-UC-FRET | CDKN2Agene | — | — | 0.1% | Up-conversion nanoparticles (UCNPs), SYTOX orange dye | 5′-biotin-TTATTAGAGGGTGGGGCGGATCGC-3′ |
|
| Detection method | Biomarker | Clinical sample | Linear range | LOD | Nanomaterial | Sequences of detection probe | Ref. |
|---|---|---|---|---|---|---|---|
| FRET | CDKN2A, TFPf2, CHFR | Synthesized sequence | — | — | Quantum dots, FRET linker probes (FLPs) | CDKN2A |
|
| Sense: TTATTAGAGGGTGGGGCGGATCGC | |||||||
| Anti-sense: GACCCCGAACCGCGACCGTAA | |||||||
| FLP: CTACCTACTCTCCCCCTCTCCRCAACCRCC | |||||||
| TFPf2 | |||||||
| Sense: GTTCGTTGGGTAAGGCGTTC | |||||||
| Anti-sense: CATAAAACGAACACCCGAACCG | |||||||
| FLP: ACCGCGCACCTCCTCCCGCCAA | |||||||
| CHFR | |||||||
| Sense: GTTATTTTCGTGATTCGTAGGCGAC | |||||||
| Anti-sense: CGAAACCGAAAATAACCCGCG | |||||||
| FLP: CGCTCGACCATCTTTAATCCTAACCAAACGACTTC | |||||||
| FRET | PCDHGB6, HOXA9 and RASSF1A | Lung adenocarcinoma and adjacent nontumorous tissues | — | Up to 90% | Amino-CdSe/CdS/ZnS QDs | PCDHGB6 |
|
| GATGTACACCTGCATTTTCG | |||||||
| CGTTCGCTCGGGTTCTCGCT | |||||||
| HOXA9 | |||||||
| CCAACGGGTGAGAATAAAC | |||||||
| AAAAACTACAAGTGGCATGA | |||||||
| RASSF1A | |||||||
| AAGATCACGGTCCAGCCTC | |||||||
| CTTCGTCCCCTCCTCACAC | |||||||
| PCDHGB6, HOXA9 and RASSF1A | NSCLC tissue samples and noninvasive bronchial brushing specimens | — | Sensitivity of 92% (AUC1/40.977, Po0.001) and 80% (AUC1/40.907, Po0.001) | Quantum dots | — |
| |
| SPR | Adenomatous polyposis coli | Synthesized sequence | — | 5 pmol | — | 5′-biotin-CTGmCGGAGTGmCGGGTmCGGGAAGmCGG-3′ |
|
| SPR | — | MCF7 cell | 0 to 400 nM | 100 nM | — | — |
|
| SPR | — | — | 0.5 to 120 U/mL | 0.2 U/mL | Au nanorod | — |
|
| SERS | CDKN2/p16/MTS1 (p16) | Synthesized sequence | — | 3 pM | AuNPs | 5′-SH-C6-TAC CTA CTC TAC CCC TCTCC-3′ |
|
| SERS | Cancer-related genes cadherin 1 (CDH1) and retinoic acid receptor beta (RARB) | Synthesized sequence | — | — | — | CDH1 |
|
| Methylated probe (CMP): 5′-TAA TTT TAG GTT AGA GGG TTA TmCG mCG -3′ | |||||||
| Unmethylated probe (CUMP): 5′-TAA TTT TAG GTT AGA GGG TTA TTG TG-3′ | |||||||
| Methylated target (CMT): 5′-CG CGA TAA CCC TCT AAC CTA AAA TTA-3′ | |||||||
| Unmethylated target (CUMT): 5′-CA CAA TAA CCC TCT AAC CTA AAA TTA-3′ | |||||||
| RARB | |||||||
| Methylated probe (RMP): 5′-GGT TAG TAG TTmCGGG TAG GGT TTA TmC-3′ | |||||||
| Unmethylated probe (RUMP): 5′- GGT TAG TAG TTTGGG TAG GGT TTA TT-3′ | |||||||
| Methylated target (RMT): 5′-GAT AAA CCC TAC CCG AAC TAC TAA CC-3′ | |||||||
| Unmethylated target (RUMT): 5′-AAT AAA CCC TAC CCA AAC TAC TAA CC-3′ | |||||||
| SERS | Real cell sample | — | 1.8 pmol L-1 | Wrapped graphene-Ag array, AuNPs | — |
|
| Detection method | Biomarker | Clinical sample | Linear range | LOD | Nanomaterial | Sequences of detection probe | Ref. |
|---|---|---|---|---|---|---|---|
| SERS | MDA-MB-231, MDAMB-468 and HCC1937 cell lines, | Synthetic targets, breast cancer cell lines and a serum-derived DNA sample | — | 0.5 pM | AuNPs, 4-mercapto-3-nitro benzoic acid (MNBA), 4-mercaptobenzoic acid (MBA) | Capture probe HS-AGTTGTGCAGGTGGT |
|
| SERS detection probe 1 HS-CAGATCGTCATGTTC | |||||||
| SERS detection probe 2 HS-TCTGCACCAATGTAC | |||||||
| Colorimetry | GSPTP1 gene | Urine | — | 5% methylation differences | MBD magnetic beads, SA-HRP | Forward primer: AACCCCCTTATCCCTCCGTCGTGTGGCTTTTAC |
|
| Reverse primer: AAACAGGTTCCTCCGAAGATTTCACACAACACT | |||||||
| Colorimetry | CpG islands of microRNA 9–1 | Cancer cell line | — | — | Gold nanoparticle | No reported |
|
| Colorimetry | — | Human serum | 20 to 120 nM | 0.13% | Gold nanoparticle | No reported |
|
| Colorimetry | p16/CDKN2 promoter | Breast cancer samples | 100 fM to 10 nM | 93 fM | 3,3′,5,5′-Tetramethylbenzidine | Methylated DNA: CGAGCTGCCTGGAGTTGCGTTCCAGGCGTmCGGCmCC |
|
| CTGGGCCGTCACCGCG | |||||||
| Unmethylated DNA: CGAGCTGCCTGGAGTTGCGTTCCAGGCGTCCGGCC | |||||||
| CCTGGGCCGTCACCGCG | |||||||
| Circular template: CACGCGATCCGCCCCACCCTCCGCGGTGACGGCCCAG | |||||||
| GAATTCGTGTAACTACACGAATTCCAACCGCCGAACG | |||||||
| Primer: ACCAAGAGCAACTACACGAATTC | |||||||
| Capture probe: HOOC-AACCGTCTTCCAAGAGACCTTCTCCAGGCAGCTC G | |||||||
| Biotinylated probe: GCGATCCGCCCCA-biotin |